Breast cancer remains the most common malignancy in women worldwide, prompting intense interest in artificial intelligence (AI) to enhance diagnostic accuracy and efficiency. This article reviews both established clinical AI tools and cutting-edge research developments for breast cancer diagnosis, with a focus on the United States (US), United Kingdom (UK), and Central Asia (Uzbekistan and Tajikistan). We outline current AI-assisted diagnostic applications in imaging—particularly mammography—that are in clinical use, including FDA-cleared decision-support systems, and discuss their variable adoption in healthcare practice. Recent advances from 2022–2025 are highlighted, such as deep-learning models that match or surpass radiologist performance in detecting breast malignancies on imaging, AI-driven risk-prediction models, and digital-pathology algorithms for tumor grading and metastasis detection. We also examine regional initiatives: large prospective trials in the UK integrating AI into national screening, U.S. deployments and regulatory approvals, and efforts to introduce AI diagnostics in Uzbekistan’s healthcare system amid resource constraints. The role of big data is underscored, as massive annotated datasets and multi-center collaborations have enabled these AI innovations. Challenges—including data quality, bias, integration into clinical workflows, and the need for local capacity in Central Asia—are discussed. Overall, AI-driven tools are poised to augment breast-cancer screening and diagnosis, improving early detection especially in settings with limited specialists, while ongoing research and trials continue to refine their safety and effectiveness.